Literature DB >> 9311511

Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer.

K G Nielsen1, M Skov, B Klug, M Ifversen, H Bisgaard.   

Abstract

The output and size distribution of aerosols from dry powder inhalers are dependent on the flow rate through the device. Therefore, in an in vivo study, we examined the flow-dependency of the effect of formoterol when delivered from a dry powder inhaler, the Aerolizer, in a flow range relevant to schoolchildren. In a preliminary study comprising 126 asthmatic children aged 3-10 yrs, the relationship between age and peak inspiratory flow (PIF) rate through the Aerolizer was determined. Mean PIF was 104 L.min-1 and all children aged > 5 yrs performed a PIF > 60 L.min-1. Sixteen children aged 8-15 yrs with exercise-induced asthma (EIA) took part in the main trial comparing the protective effect of 12 micrograms formoterol inhaled at 60 and 120 L.min-1. The effect from high and low inspiratory flow was judged from the protective effect against EIA 12 h after drug administration. The decrease in forced expiratory volume in one second (FEV1) after exercise was 34% on the placebo day, but only 15% when formoterol was inhaled at the high flow rate. This difference was statistically significant. The decrease in FEV1 was 23% after treatment with formoterol inhaled at the low flow rate, that was not significantly different from placebo or from high-flow formoterol treatment. These clinical findings correspond with the in vitro findings of flow-dependent fine particle mass from the Aerolizer, and corroborate the relationship between fine particle mass of aerosol and clinical effect. The results indicate a flow-dependent effect of formoterol dry powder inhaled from the Aerolizer, within the range of inspiratory flow rate obtainable by school-children. This questions its applicability in children with asthma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311511     DOI: 10.1183/09031936.97.10092105

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  14 in total

Review 1.  The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Authors:  Jeffry Weers; Andy Clark
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

Review 2.  Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.

Authors:  R A Bartow; R N Brogden
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

Review 3.  Exercise-induced asthma in children.

Authors:  John Massie
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 4.  Beta2-agonists and exercise-induced asthma.

Authors:  Sandra D Anderson; Corinne Caillaud; John D Brannan
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 5.  Long-acting beta 2-adrenoceptor agonists and exercise-induced asthma: lessons to guide us in the future.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 6.  Formoterol delivered by Turbuhaler: in pediatric asthma.

Authors:  Susan M Cheer; Gregory T Warner; Stephanie E Easthope
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 7.  Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.

Authors:  Lorraine Murphy; Stephen Rennard; James Donohue; Mathieu Molimard; Ronald Dahl; Kai-Michael Beeh; Juergen Dederichs; Hans-Jürgen Fülle; Mark Higgins; David Young
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 8.  Exercise-induced bronchoconstriction in asthmatic children: a comparative systematic review of the available treatment options.

Authors:  Tomasz Grzelewski; Iwona Stelmach
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 9.  Airmax: a multi-dose dry powder inhaler.

Authors:  Gillian M Keating; Diana Faulds
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 10.  The lung as a route for systemic delivery of therapeutic proteins and peptides.

Authors:  R U Agu; M I Ugwoke; M Armand; R Kinget; N Verbeke
Journal:  Respir Res       Date:  2001-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.